Owlstone Medical has been featured in Pharmaphorum's "Deep Dive Oncology" magazine. The article lists 5 companies leading the next generation of innovation in the cancer space, and describes our Breath Biopsy® platform, including our lung cancer collaboration with the NHS through the LuCID clinical trial.
Five tech companies advancing against cancer
Marco Ricci - May 2017
Excerpt from the article:
“The advantage to VOCs is that they can be picked up earlier than signatures searched for in liquid biopsies, meaning cancer can be diagnosed earlier and treated more effectively.”
For more information please contact:
Sarah Jeffery, Zyme Communications
+44 (0)7771 730 919